A 55-year-old man is evaluated in the hospital for a new-onset headache. He was admitted 5… — USMLE Step 2 CK

A 55-year-old man is evaluated in the hospital for a new-onset headache. He was admitted 5 days ago for a deep venous thrombosis of the right lower extremity and was started on intravenous unfractionated heparin. His temperature is $37.1^\circ\text{C}$ ( $98.8^\circ\text{F}$ ), blood pressure is $128/82\text{ mm Hg}$ , pulse is $88/\text{min}$ , and respirations are $16/\text{min}$ . Physical examination is unremarkable, with no signs of active bleeding. Laboratory studies on admission showed a platelet count of $240,000/\mu\text{L}$ . Today, his laboratory studies show a hemoglobin of $13.5\text{ g/dL}$ , a leukocyte count of $7,500/\mu\text{L}$ , and a platelet count of $105,000/\mu\text{L}$ . Which of the following is the most appropriate next step in management?

Discontinue unfractionated heparin and initiate a non-heparin anticoagulantCevap
B
Continue unfractionated heparin and observe daily
C
Discontinue unfractionated heparin and start warfarin monotherapy
D
Transfuse pooled platelets immediately
E
Perform a bone marrow aspiration and biopsy

Cevap

Discontinue unfractionated heparin and initiate a non-heparin anticoagulant

The patient has developed type 2 heparin-induced thrombocytopenia (HIT), a life-threatening, immune-mediated complication characterized by antibodies against the heparin-platelet factor 4 (PF4) complex. This leads to platelet activation and a paradoxical hypercoagulable state. The hallmark of HIT is a platelet count drop of greater than 50% from baseline, typically occurring 5 to 10 days after starting heparin. The most critical initial step in management is to immediately discontinue all heparin products to stop the immune stimulus. However, because these patients remain at very high risk for catastrophic arterial and venous thrombosis, simply stopping heparin is insufficient. They must immediately be transitioned to a non-heparin anticoagulant, such as a direct thrombin inhibitor (e.g., argatroban, bivalirudin) or an indirect factor Xa inhibitor (e.g., fondaparinux).

Adım Adım Çözüm

Analyze the change in the patient's platelet count over time.

The platelet count has fallen from

240,000/\mu\text{L}

105,000/\mu\text{L}

over 5 days.

Tracking platelet trends in a patient on heparin is necessary to screen for heparin-induced thrombocytopenia (HIT).

Correlate the timing and magnitude of the platelet drop with the diagnosis of HIT.

A drop of greater than 50% occurring 5 to 10 days after heparin exposure strongly suggests type 2 HIT.

Type 2 HIT is an immune-mediated disorder caused by antibodies against heparin-platelet factor 4 complexes, which typically takes 5-10 days to develop.

Determine the best initial management for suspected HIT.

All heparin products must be stopped, and an alternative anticoagulant must be started to prevent life-threatening thrombosis.

Even though platelets are low, HIT is a prothrombotic state. A non-heparin anticoagulant (like argatroban or fondaparinux) is required.

Anahtar Kavram

Heparin-induced thrombocytopenia (HIT) typically presents as a >50% drop in platelet count 5-10 days after initiating heparin therapy. Management requires immediate cessation of all heparin and initiation of a non-heparin anticoagulant.

Soru

Cevap

Adım Adım Çözüm

Anahtar Kavram

Sık Yapılan Hatalar

Konular

Bu konudan daha fazla soru